Related Experiment Video
Updated: May 30, 2026
07:51
Pull-down of Calmodulin-binding Proteins
Published on: January 23, 2012
Cardiac calmodulin kinase: a potential target for drug design
T Bányász1, N Szentandrássy, A Tóth
1Department of Physiology, University of Debrecen, Nagyerdei krt. 98. H-4012 Debrecen, Hungary. banyasz@phys.dote.hu
Current Medicinal Chemistry
|July 22, 2011
Summary
Implantable cardioverter defibrillators are effective for malignant arrhythmias, but drug therapies are still needed. Calcium/calmodulin-dependent kinase II (CaMKII) inhibition shows promise as a new therapeutic strategy for heart disease.
Area of Science:
- Cardiology
- Molecular Biology
- Pharmacology
Background:
- Implantable cardioverter defibrillators (ICDs) are primary treatments for malignant arrhythmias.
- Antiarrhythmic drug therapy remains crucial for arrhythmias unresponsive to ICDs and for cost-effectiveness.
- Current ion channel blocker therapies have limited success and significant risks.
Purpose of the Study:
- To explore calcium/calmodulin-dependent kinase II (CaMKII) as a novel therapeutic target for cardiac arrhythmias.
- To review the role of CaMKII in cardiac function, hypertrophy, and arrhythmogenesis.
- To discuss CaMKII's structural and functional properties and its impact on ion channels.
Main Methods:
- Literature review of studies on cardiac ion channels, antiarrhythmic drugs, and CaMKII.
- Analysis of evidence linking CaMKII activity to cardiac dysfunction and arrhythmias.
- Examination of CaMKII's role in hypertrophy and functional remodeling.
Main Results:
- CaMKII activity is elevated in failing hearts and contributes to hypertrophy and arrhythmogenic activity.
- Inhibition of CaMKII has demonstrated potential in mitigating cardiac remodeling and reducing arrhythmias.
- CaMKII influences cardiac function through its effects on ion channels.
Conclusions:
- CaMKII represents a promising upstream molecular target for novel antiarrhythmic strategies.
- Targeting CaMKII may offer an effective alternative or adjunct to current therapies.
- Further research into CaMKII inhibition could lead to improved treatments for heart disease.
Related Concept Videos
01:16Calmodulin-dependent Signaling
Calmodulin (CaM) is a calcium-binding protein in eukaryotes that controls various calcium-regulated cellular processes. It has four calcium-binding sites that bind calcium to form the calcium-calmodulin ( Ca2+-CaM) complex. GPCR stimulation increases the calcium levels in the cells that bind to CaM and induces a conformational change.
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Transducer Mechanism: Enzyme-Linked Receptors
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...